Theravance Biopharma TBPH Change in Other Liabilities
Change in Other Liabilities at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's change in other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's change in other liabilities?
- Theravance Biopharma (TBPH) reported change in other liabilities of -$69K in Q1 2026.
- How has Theravance Biopharma's change in other liabilities changed year-over-year?
- Theravance Biopharma's change in other liabilities decreased by 201.5% year-over-year, from $68K to -$69K.
- What is the long-term trend for Theravance Biopharma's change in other liabilities?
- Over 2 years (2022 to 2024), Theravance Biopharma's change in other liabilities has grown at a 0.7% compound annual growth rate (CAGR), from -$525K to -$532K.
- What does change in other liabilities mean?
- Change in miscellaneous liabilities affecting operating cash flow.